‘Mass Spectrometry Market Worth Over $3.8 Billion In 2017’ Says Visiongain Report

28 August 2017
Pharma

Visiongain’s new report The Mass Spectrometry Market Forecast 2017-2027 – Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, TOF, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography indicates that the global mass spectrometry market will see over $3.8bn in revenue in 2017.

The lead analyst of the report said:

“The mass spectrometry market is expected to experience considerable growth over the forecast period. The main drivers for the growth include the applications of the mass spectrometry in wide range of areas, technological advancements and adoption/acceptability of new technology by the government to address the healthcare challenges. The increasing disease burden and identification of antibacterial resistant strains is leading to therapeutical advancements, drug discovery and increase research and development activities to address this situation. The high-speed, accurate, sample analysis of simple to complex molecules/products by the mass spectrometry is leading to its increased demand in the areas such as clinical research, proteomic, metabolomics, and forensics including many others.”
The 183-page report contains 111 tables, charts and graphs that add visual analysis in order to explain developing trends within the mass spectrometry market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading mass spectrometry submarkets, segmented by technology, with forecasts for single and hybrid mass spectrometry. The market is also segmented by product, and includes forecasts for Ion Trap, Quadrupole, TOF, Triple Quadrupole, Quadrupole-TOF and Fourier Transform Mass Spectrometry. The report also includes forecasts for the applications of mass spectrometry, including academic, biotech, agriculture, contract research, hospital, environmental and material usage.

The 183-page report offers market forecasts and analysis for 4 regional and 12 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the field in mass spectrometry technology.

The Mass Spectrometry Market Forecast 2017-2027 – Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, TOF, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography report will be of value to anyone who wants to better understand the mass spectrometry market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the mass spectrometry industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever